19 Oct, 2018 – Dallas, TX (October 19, 2018) – Evolve presented “A prospective, open-label, multicenter study of the efficacy, safety, tolerability, and pharmacokinetics of PlasmaCapTM IG (Immunoglobulin) in adults and children with primary immunodeficiency” and “PlasmaCap EBA™, an innovative method of isolating plasma proteins from human plasma”. Abstracts available here.